Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls

Psychiatry Research - Neuroimaging

Volumn 234, Issue 1, 2015, Pages 84-89

  Zugman, Andre ^a,b   Pedrini, Mariana ^a   Gadelha, Ary ^a   Kempton, Matthew J ^b   Noto, Cristiano S ^a   Mansur, Rodrigo B ^a   Santoro, Marcos L ^a   Gama, Clarissa S ^c   Bressan, Rodrigo A ^a   McGuire, Philip ^b   Jackowski, Andrea P ^a   Brietzke, Elisa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

BDNF; Cortical thickness; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BLOOD SAMPLING; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; IMAGE PROCESSING; MALE; NERVE CELL PLASTICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RIGHT HEMISPHERE; SCHIZOPHRENIA; AMYGDALA; BLOOD; BRAIN CORTEX; ORGAN SIZE; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; AMYGDALA; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; ORGAN SIZE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84948719190     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2015.08.009     Document Type: Article

References (55)

1. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 1993, 22:39-44.
2. American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 1997, 154:1-63.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, Author, Washington, DC, (text revision). 4th ed.
4. Asevedo E., Gadelha A., Noto C., Mansur R.B., Zugman A., Belangero S.I., Berberian A.A., Scarpato B.S., Leclerc E., Teixeira A.L., Gama C.S., Bressan R.A., Brietzke E. Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. J. Psychiatr. Res. 2013, 47:1376-1382.
5. Bressan R.A., Chaves A.C., Shirakawa I., de Mari J. Validity study of the Brazilian version of the Calgary Depression Scale for schizophrenia. Schizophren. Res. 1998, 32:31-39.
6. Brietzke E., Mansur R.B., Soczynska J., Powell A.M., McIntyre R.S. A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2012, 39:1-8.
7. Dale A.M., Sereno M.I. Improved localization of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction: a linear approach. J. Cognit. Neurosci. 1993, 5:162-176.
8. Del-Ben C.M., Vilela J.A.A., Crippa J.Ad.S., Hallak J.E.C., Labate C.M., Zuardi A.W. Reliability of the structured clinical interview for DSM-IV-clinical version translated into Portuguese. Rev. Bras. Psiquiatr. 2001, 23:156-159.
9. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophren. Res. 2001, 52:79-86.
10. Ehrlich S., Geisler D., Yendiki A., Panneck P., Roessner V., Calhoun V.D., Magnotta V.A., Gollub R.L., White T. Associations of white matter integrity and cortical thickness in patients with schizophrenia and healthy controls. Schizophren. Bull. 2014, 40:665-674.
11. Eisenberg D.P., Ianni A.M., Wei S.M., Kohn P.D., Kolachana B., Apud J., Weinberger D.R., Berman K.F. Brain-derived neurotrophic factor (BDNF) Val(66)Met polymorphism differentially predicts hippocampal function in medication-free patients with schizophrenia. Mol. Psychiatry 2013, 18:713-720.
12. Favalli G., Li J., Belmonte-de-Abreu P., Wong A.H., Daskalakis Z.J. The role of BDNF in the pathophysiology and treatment of schizophrenia. J. Psychiatr. Res. 2012, 46:1-11.
13. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. USA 2000, 97:11050-11055.
14. Fischl B., Liu A., Dale A.M. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans. Med. Imaging 2001, 20:70-80.
15. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
16. Fischl B., Salat D.H., van der Kouwe A.J., Makris N., Segonne F., Quinn B.T., Dale A.M. Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004, 23(Suppl. 1):S69-S84.
17. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999, 9:195-207.
18. Fischl B., Sereno M.I., Tootell R.B., Dale A.M. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum. Brain Mapp. 1999, 8:272-284.
19. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. 2007, 420:45-48.
20. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol. Psychiatry 2011, 16:960-972.
21. Haijma S.V., Van Haren N., Cahn W., Koolschijn P.C., Hulshoff Pol H.E., Kahn R.S. Brain volumes in schizophrenia: a meta-analysis in over 18,000 subjects. Schizophren. Bull. 2013, 39:1129-1138.
22. Haro J., Kamath S., Ochoa So, Novick D., Rele K., Fargas A., Rodriguez M., Rele R., Orta J., Kharbeng A. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. 2003, 107:16-23.
23. Kapczinski F., Frey B.N., Kauer-Sant'Anna M., Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev. Neurother. 2008, 8:1101-1113.
24. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophren. Bull. 1987, 13:261-276.
25. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., Goff D., West W.C., Williams S.C., van der Kouwe A.J., Salat D.H., Dale A.M., Fischl B. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60:878-888.
26. Lima M.Sd, Soares B.Gd.O., Paoliello G., Vieira R.M., Martins C.M., Mota Neto J.Id, Ferrão Y., Schirmer D.A., Volpe F.M. The Portuguese version of the Clinical Global Impression-Schizophrenia Scale: validation study. Rev. Bras. Psiquiatr. 2007, 29:246-249.
27. Lotfipour S., Ferguson E., Leonard G., Perron M., Pike B., Richer L., Seguin J.R., Toro R., Veillette S., Pausova Z., Paus T. Orbitofrontal cortex and drug use during adolescence: role of prenatal exposure to maternal smoking and BDNF genotype. Arch. Gen. Psychiatry 2009, 66:1244-1252.
28. Lyoo I.K., Kim J.E., Yoon S.J., Hwang J., Bae S., Kim D.J. The neurobiological role of the dorsolateral prefrontal cortex in recovery from trauma. Longitudinal brain imaging study among survivors of the South Korean subway disaster. Arch. Gen. Psychiatry 2011, 68:701-713.
29. Muglia P., Vicente A.M., Verga M., King N., Macciardi F., Kennedy J.L. Association between the BDNF gene and schizophrenia. Mol. Psychiatry 2003, 8:146-147.
30. Neves-Pereira M., Cheung J.K., Pasdar A., Zhang F., Breen G., Yates P., Sinclair M., Crombie C., Walker N., St, Clair D.M. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol. Psychiatry 2005, 10:208-212.
31. Nieto R., Kukuljan M., Silva H. BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Frontiers in Psychiatry 2013, 4:45.
32. Niitsu T., Ishima T., Yoshida T., Hashimoto T., Matsuzawa D., Shirayama Y., Nakazato M., Shimizu E., Hashimoto K., Iyo M. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 2014, 215:268-273.
33. Noto C.S., Gadelha A., Belangero S.I., Smith M.A., de Aguiar B.W., Panizzuti B., Mari Jde J., Gama C.S., Bressan R.A., Brietzke E. Association of biomarkers and depressive symptoms in schizophrenia. Neurosci. Lett. 2011, 505:282-285.
34. Pedrini M., Chendo I., Grande I., Lobato M.I., Belmonte-de-Abreu P.S., Lersch C., Walz J., Kauer-Sant'anna M., Kapczinski F., Gama C.S. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci. Lett. 2011, 491:207-210.
35. Pedrini M., Massuda R., Fries G.R., de Bittencourt Pasquali M.A., Schnorr C.E., Moreira J.C., Teixeira A.L., Lobato M.I., Walz J.C., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J. Psychiatr. Res. 2012, 46:819-824.
36. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32.
37. Reis H.J., Nicolato R., Barbosa I.G., Teixeira do Prado P.H., Romano-Silva M.A., Teixeira A.L. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci. Lett. 2008, 439:157-159.
38. Rizos E., Papathanasiou M.A., Michalopoulou P.G., Laskos E., Mazioti A., Kastania A., Vasilopoulou K., Nikolaidou P., Margaritis D., Papageorgiou C., Liappas I. A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia. PloS One 2014, 9:e87997.
39. Rizos E.N., Papathanasiou M., Michalopoulou P.G., Mazioti A., Douzenis A., Kastania A., Nikolaidou P., Laskos E., Vasilopoulou K., Lykouras L. Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophren. Res. 2011, 129:201-204.
40. Rudge J.S., Mather P.E., Pasnikowski E.M., Cai N., Corcoran T., Acheson A., Anderson K., Lindsay R.M., Wiegand S.J. Endogenous BDNF protein is increased in adult rat hippocampus after a kainic acid induced excitotoxic insult but exogenous BDNF is not neuroprotective. Exp. Neurol. 1998, 149:398-410.
41. Segonne F., Dale A.M., Busa E., Glessner M., Salat D., Hahn H.K., Fischl B. A hybrid approach to the skull stripping problem in MRI. Neuroimage 2004, 22:1060-1075.
42. Segonne F., Pacheco J., Fischl B. Geometrically accurate topology-correction of cortical surfaces using nonseparating loops. IEEE Trans. Med. Imaging 2007, 26:518-529.
43. Skilleter A.J., Weickert C.S., Vercammen A., Lenroot R., Weickert T.W. Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia. Psychol. Med. 2015, 45:841-854.
44. Sled J.G., Zijdenbos A.P., Evans A.C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 1998, 17:87-97.
45. Song X., Fan X., Li X., Kennedy D., Pang L., Quan M., Chen X., Gao J., Zhang W., Zhang J., Lv L. Serum levels of BDNF, folate and homocysteine: in relation to hippocampal volume and psychopathology in drug naive, first episode schizophrenia. Schizophren. Res. 2014, 159:51-55.
46. Song X., Quan M., Lv L., Li X., Pang L., Kennedy D., Hodge S., Harrington A., Ziedonis D., Fan X. Decreased cortical thickness in drug naive first episode schizophrenia: in relation to serum levels of BDNF. J. Psychiatr. Res. 2015, 60:22-28.
47. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., Koizumi S., Wakabayashi K., Takahashi H., Someya T., Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiatry 2000, 5:293-300.
48. Vicario-Abejon C., Owens D., McKay R., Segal M. Role of neurotrophins in central synapse formation and stabilization. Nat. Rev. Neurosci. 2002, 3:965-974.
49. Voineskos A.N., Lerch J.P., Felsky D., Shaikh S., Rajji T.K., Miranda D., Lobaugh N.J., Mulsant B.H., Pollock B.G., Kennedy J.L. The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. Arch. Gen. Psychiatry 2011, 68:198-206.
50. Wang C., Zhang Y., Liu B., Long H., Yu C., Jiang T. Dosage effects of BDNF Val66Met polymorphism on cortical surface area and functional connectivity. J. Neurosci. 2014, 34:2645-2651.
51. Woods B.T., Ward K.E., Johnson E.H. Meta-analysis of the time-course of brain volume reduction in schizophrenia: implications for pathogenesis and early treatment. Schizophren. Res. 2005, 73:221-228.
52. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64:663-667.
53. Worsley K.J., Andermann M., Koulis T., MacDonald D., Evans A.C. Detecting changes in nonisotropic images. Hum. Brain Mapp. 1999, 8:98-101.
54. Zai G.C., Zai C.C., Chowdhury N.I., Tiwari A.K., Souza R.P., Lieberman J.A., Meltzer H.Y., Potkin S.G., Muller D.J., Kennedy J.L. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2012, 39:96-101.
55. Zugman A., Gadelha A., Assuncao I., Sato J., Ota V.K., Rocha D.L., Mari J.J., Belangero S.I., Bressan R.A., Brietzke E., Jackowski A.P. Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia. Schizophren. Res. 2013, 148:81-86.